FDA Brief

Warning letters Food

FDA warning letter to

Western Herb Products, Inc.

MediumIssued Dec 7, 2021Posted Dec 28, 2021Office of Human and Animal Food Operations – West Division 6

FDA warned Western Herb Products over adulterated, misbranded Wormwood/Aloes capsules and serious dietary supplement manufacturing violations.

What happened

FDA inspected Western Herb Products’ dietary supplement facility in Index, Washington, on May 3, 4, and 12, 2021. FDA said the firm did not establish required current good manufacturing practice (CGMP) specifications, manufacturing and batch records, quality control procedures, or complaint procedures, and that its Wormwood/Aloes product was misbranded. FDA reviewed the firm’s May 31, 2021 response and found the proposed corrections inadequate.

What FDA found

  1. The firm did not establish required written specifications for ingredients, in-process steps, and finished Wormwood/Aloes capsules.

    21 CFR 111.70(a), (b), (c), (e)
  2. The master manufacturing record for Wormwood/Aloes lacked required information such as ingredient strength, component list, weights, yield limits, and instructions.

    21 CFR 111.205(a), 21 CFR 111.210
  3. Batch production records lacked required details such as equipment identity, cleaning dates, component weights, yields, test results, and quality review.

    21 CFR 111.255(a), 21 CFR 111.260
  4. The firm had no written quality control procedures for material review, disposition decisions, and approving or rejecting processing.

    21 CFR 111.103
  5. The firm had no adequate written procedure for reviewing and investigating product complaints.

    21 CFR 111.553, 21 CFR 111.560
  6. The Wormwood/Aloes label did not correctly identify the plant part used, and other label information did not comply.

    section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)]; 21 CFR 101.4(h)(1)

What FDA wants

FDA tells the company to respond in writing within 15 working days of receipt, describing specific corrective steps, explaining how recurrence will be prevented, and providing related documents. If corrections cannot be completed in that time, the company must state why and give a completion date.

Who should pay attention

  • dietary supplement brands using contract manufacturers
  • retailers and distributors of herbal supplement capsules
  • quality teams handling botanical identity and supplier specifications

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Mineral BioSciences, LLC

    Mineral BioSciences’ Totala and Ionicell supplements were flagged as unapproved new drugs and misbranded, with manufacturing violations.

    High risk
  2. Imu-Tek Animal Health, Incorporated

    FDA warns Imu-Tek Animal Health over unapproved drug claims and manufacturing failures for Colostrom-5 products.

    High risk
  3. Meta Labs Pharmaceuticals, LLC

    FDA warns Meta Labs its supplements are unapproved drugs and have serious manufacturing violations.

    High risk
  4. Hearthy Foods, Inc.

    FDA cited Hearthy Foods after an inspection for CGMP violations in RTE whey protein and dietary supplements, including allergen and pest issues.

    High risk